NAMS Strangle Strategy
NAMS (NewAmsterdam Pharma Company N.V.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.
NAMS (NewAmsterdam Pharma Company N.V.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $4.41B, a beta of 0.03 versus the broader market, a 52-week range of 16.785-42.205, average daily share volume of 1.0M, a public-listing history dating back to 2021, approximately 68 full-time employees. These structural characteristics shape how NAMS stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.03 indicates NAMS has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure.
What is a strangle on NAMS?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
Current NAMS snapshot
As of May 15, 2026, spot at $35.32, ATM IV 77.30%, IV rank 33.61%, expected move 22.16%. The strangle on NAMS below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this strangle structure on NAMS specifically: NAMS IV at 77.30% is mid-range versus its 1-year history, so strategy selection should anchor more to the directional thesis than to the IV regime, with a market-implied 1-standard-deviation move of approximately 22.16% (roughly $7.83 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated NAMS expiries trade a higher absolute premium for lower per-day decay. Position sizing on NAMS should anchor to the underlying notional of $35.32 per share and to the trader's directional view on NAMS stock.
NAMS strangle setup
The NAMS strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With NAMS near $35.32, the first option leg uses a $37.09 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed NAMS chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 NAMS shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $37.09 | N/A |
| Buy 1 | Put | $33.55 | N/A |
NAMS strangle risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
NAMS strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on NAMS. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use strangle on NAMS
Strangles on NAMS are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the NAMS chain.
NAMS thesis for this strangle
The market-implied 1-standard-deviation range for NAMS extends from approximately $27.49 on the downside to $43.15 on the upside. A NAMS long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current NAMS IV rank near 33.61% is mid-range against its 1-year distribution, so the IV signal is neutral; the strangle thesis on NAMS should anchor more to the directional view and the expected-move geometry. As a Healthcare name, NAMS options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to NAMS-specific events.
NAMS strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. NAMS positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move NAMS alongside the broader basket even when NAMS-specific fundamentals are unchanged. Always rebuild the position from current NAMS chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on NAMS?
- A strangle on NAMS is the strangle strategy applied to NAMS (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With NAMS stock trading near $35.32, the strikes shown on this page are snapped to the nearest listed NAMS chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are NAMS strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the NAMS strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 77.30%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a NAMS strangle?
- The breakeven for the NAMS strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current NAMS market-implied 1-standard-deviation expected move is approximately 22.16%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on NAMS?
- Strangles on NAMS are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the NAMS chain.
- How does current NAMS implied volatility affect this strangle?
- NAMS ATM IV is at 77.30% with IV rank near 33.61%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.